Composition and method for maintaining blood glucose level

Details Composition and method for maintaining blood glucose level Composition and method for maintaining blood glucose level

2001-08-21

2004-03-09

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S465000, C424S484000, C424S486000, C424S488000, C424S468000, C424S451000, C424S452000, C424S457000, C514S772000, C514S772100

Reexamination Certificate

active

06703045

ABSTRACT:

CROSS-REFERENCE TO RELATED APPLICATIONS
Not Applicable
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable
REFERENCE TO A COMPUTER PROGRAM APPENDIX
Not Applicable
INCORPORATION BY REFERENCE
The following publications which are identified herein using a number inside parenthesis (e.g., (1)) are hereby incorporated by reference:
(1) American Diabetes Association. Diabetes 1996 Vital Statistics. Rockville, Md.: American Diabetes Association, 1996.
(2) Harris, M. I., Cowie, C. C., Stern, M. P. eds. Diabetes in America, 2nd. ed. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases.
NIH Publication No
. 95-1468, 1995.
(3) Clark, C. M., Vinicor, F. Introduction: Risks and benefits of intensive management in non-insulin-dependent diabetes mellitus. The Fifth Regensrief Conference.
Ann Intern Med
, 124(1, pt 2), 81-85, 1996.
(4) Porte, J. and Schwartz, M. W., Diabetes complications: Why is glucose potentially toxic?,
Science
, 272, 699-700, 1996.
(5) Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S. E., Kern, T. S., Ballas, L. M., Heath, W. F., Stramm, L. E., Feener, E. P. and King, G. L., Amelioration of vascular dysfunctions in diabetic rats by an oral PKC &bgr;inhibitor,
Science
, 272, 728-731, 1996.
(6) UKPDS Group. UK Prospective Diabetes Study 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
Lancet
, 352, 837-853, 1998.
(7) Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylurea.
Arch Int Med
, 8, 25, 1997.
(8) Tight control for type 2 diabetes.
Health News
, 10, 25, 1998.
(9) Boyle, P. J., Kempers, S. F., O'Connor, A. M. and Nagy, R. J., Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus,
New Eng J. Med
333(26), 1726-1731, 1995.
(10) Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med
, 329, 977-986, 1993.
(11) American Diabetes Association. Implications of the Diabetes Control and Complications Trial.
Diabetes Spec
6(4), 225-227, 1993.
(12) Lewin, D. I., Brain's adaptation to low blood sugar endangers diabetics,
J. NIH Research
, 8, 38-39, 1996.
(13) Miller, J. L., Salman, K., Shulman, L. H. and Rose, L. I., Bed time insulin added to daytime sulfonylurea improves glycemic control in uncontrolled type II diabetes,
Clin. Pharmacol. Ther
., 53 (Mar), 380-384, 1993.
(14) Shank, M. L., Prato, S. D. and DeFronzo, R. A., Bedtime insulin/daytime glipizide, effective therapy for sulfonylurea failures in NIDDM,
Diabetes,
44(2), 165-172, 1995.
(15) Labovitz, H. E., Glipizide : A second generation sulfonylurea hypoglycaemic agent,
Pharmcotherapy
, 5 (2), 63-77, 1985.
(16) Labovitz, H. E., Oral sulfonylurea hypoglycemic drugs,
Pharmacy Times
, 51, 108-116, 1985.
(17) Martindale, The Extra Pharmacopoeia, Thirtieth Edition, Eds. J. E. F. Reynolds, The Pharmaceutical Press, London, 1993.
(18) AHFS Drug Information, 1989, pp 1741-1745.
(19) Brogden, R. N., Heel, R. C., Pakes, G. E., Speight, T. M. and Avery, G. S., Glipizide : A review of its pharmacological properties and therapeutic use,
Drugs
, 18, 329-353, 1979.
(20) www.pfizer.com/hml/pi&#39:s/glucotrolxlpi.pdf.
(21) Peterson, C. M., Sims, R. V., Jones, R. L. and Rieders, F., Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes,
Diabetes care
, 5, 497-500, 1982.
(22) Feinglos, M. N. and Lebovitz, H. E., Long term safety and efficacy of glipizide,
Am. J. Med
., 25 (suppl. 5B), 60-66, 1983.
(23) Kradjan, W. A., Takeuchi, K. Y., Opheim, K. E. and Wood, F. C. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses,
Pharmacotherapy
, 15 (4), 465-471, 1995.
(24) Berelowitz, M., Fischette, C., Cefalu, W., Schade, D. S., Sutfin, T., and Kourides, I. A., Comparative efficacy of once daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM,
Diabetes Care
, 17 (12), 1460-1464, 1994.
(25) Riddle, M. C., Mcdaniel, P. A. and Tive, L. A., Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM,
Diabetes Care
, 20 (6), 992-994, 1997.
(26) Blonde, L., Guthrie, R. D., Tive, L., Fischette, C. The Glipizide GITS efficacy and safety trial study group. Glipizide GITS is effective and safe in a wide range of NIDDM patients: results of a double blind, placebo controlled efficacy and safety trial,
Diabetes
45 (suppl. 2): 285A, 1996.
(27) British Pharmacopoeia, London The Stationery Office, Volume II, pp1862, 1999,.
(28) United States Pharmacopeia XXIII National Formulary,18, United States Pharmacopeial Convention Inc. Rockville, pp707-708, 1995.
(29) Lachman, Leon, Liberman, H. A. and Kanig, J. L., The theory and Practice of Industrial Pharmacy, Varghese Publishing House, Bombay,1991.
(30) Guidance for Industry: Dissolution testing of immediate released dosage forms. FDA, August 1997.
(31) Amidon, G. L., Lennernas, H., Shah, V. P. and Crison, J. R. A., Theoretical basis for a biopharmaceutic drug classification: the correlation of In vitro drug product dissolution and in vivobioavailability, Pharm. Res., 12, 413-420, 1995.
(32) United States Pharmacopeial Convention, Inc., July 1998, In vitro-In vivo Correlation for extended release oral dosage forms, Pharmacopeial Forum Stimuli Article, 4160-4161.
(33) Guidance for Industry, Glipizide, In vivobioequivalence and In vitro dissolution testing, Division of Bioequivalence, Office of Generic drugs, 7500 standish Place, Metro Park North, Rockville, Md. 20855.
(34) United States Pharmacopeia XXIII National Formulary,18, United States Pharmacopeial Convention Inc. Rockville, Supplement I pp2465, 1995.
(35) Shenfield, G. M., Boutagy, J. S. and Webb, C. A screening test for detecting sulfonylureas in plasma,
Therapeutic Drug Monitoring
, 1990, 12, 393-397.
(36) Guidance for Industry: SUPAC-MR: modified release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls; In vitro dissolution testing and In vivobioequivalence documentation.FDA, September 1997.
(37) Shah, V. P., Tsong, Y., Sathe, P. and Liu, J. P., In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f
2
, Pharm. Res
. 15, 889-896, 1998.
(38) Tang, Y. and Gan, K., Statistical evaluation of In vitro dissolution of different brands of ciprofloxacin hydrochloride tablets and capsules,
Drug. Dev. Ind. Pharm
., 24(6), 549-552, 1998.
(39) Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products—General considerations.
(40) Hunt, G., Kearney, P. and Kellaway, I. W., Mucoadhesive polymers in drug delivery systems, in
Drug Delivery Systems
(Eds P. Johnson and J. G. Lloyd-Jones), Ellis Horwood Ltd. Chichester, UK, and VHC Verlagsgesellschaft GmbH Weinheim, Germany, pp.180-199, 1987.
(41) Sau-Hung, Leugand, S. and Robinson, J. R., Bioadhesives in drug delivery,
Polym. News
15, 333, 1990.
(42) Chen,m J. L. and Cyr, G. N., Composition producing adhesion through hydration, in Adhesion in Biological systems (Ed. R. S. Manly), Academic Press, new York and London, ch. 10, pp. 163-167, 1970,
(43) P. Bottenberg et al., Development and testing of bioadhesive fluoride containing slow release tablets for oral use,
J. Pharm. Pharmacol
., 43,457-464, 1991.
(44) Polyox Water soluble resins, NF in sustained—Release Oral pharmaceutical applications, Union Carbide, Danbury Conn., Literature#UC377.
(45) Gupta, A., Garg, S. and Khar, A. K., Measurement of bioadhesive strength of mucoadhesive buccal tablets: Design of an In vitro assembly,
Indian Drugs
, 30, 152-155, 1993.
(46) Martin, F., Physical Pharmacy, Fourth Edition, Lea and Febiger, Philad

Affiliated with

Also associated with

Rating

Composition and method for maintaining blood glucose level does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition and method for maintaining blood glucose level, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for maintaining blood glucose level will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3210776